Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3057846 | 1.00 | HPGD (0.60) | HPGDALDH1A1TSHRGAARAB9A | |
| SCHEMBL3040894 | 1.00 | HPGD (0.60) | HPGDALDH1A1TSHRGAARAB9A | |
| SCHEMBL3058204 | 0.94 | TSHR (0.60) | HPGDALDH1A1TSHRGAARAB9A | |
| SCHEMBL3058328 | 0.94 | TSHR (0.60) | HPGDALDH1A1TSHRGAARAB9A | |
| SCHEMBL3050019 | 0.89 | NPC1 (0.47) | HPGDALDH1A1TSHRRAB9AMAPT | |
| SCHEMBL3053960 | 0.89 | HPGD (0.47) | HPGDALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL3053998 | 0.89 | HPGD (0.47) | HPGDALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL3044607 | 0.89 | NPC1 (0.47) | HPGDALDH1A1TSHRRAB9AMAPT | |
| SCHEMBL3057817 | 0.89 | HPGD (0.57) | HPGDALDH1A1TSHRGAARAB9A | |
| SCHEMBL3060197 | 0.87 | HPGD (0.55) | HPGDALDH1A1TSHRGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | HPGD 756/4885ALDH1A1 15/4885TSHR 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.